-
As is often the case with science-based medicine, many great discoveries are made entirely by accident or out of an urgent necessity. Falling into the latter category was CardioTech Internationals (Woburn, Massachusetts) first pediatric implant of a synthetic coronary artery bypass graft (CABG), the first of its kind in the world.
-
Eucomed (Brussels, Belgium), the European medical technology trade association, has developed a computerized health economic model to explore the cost-effectiveness of cardiac resynchronization therapy (CRT) as compared to traditional pharmaceutical treatment for heart failure.
-
Endovascular physicians and interventional cardiologists are overwhelmingly likely to use drug-eluting stents (DES) more often in the future because they believe their costs will decrease as competition among manufacturers increases.
-
John Babitt has been named president, chief operating officer and chief financial officer of CABG Medical (Minneapolis, Minnesota). Babitt previously was an executive with BioHeart. CABG Medical develops coronary bypass devices and related items designed for use in heart surgery.
-
-
PHILADELPHIA, Pennsylvania New cardiac markers such as troponin I, troponin T and, most recently, B-type natriuretic peptide (BNP) and proBNP, have revolutionized the diagnosis of myocardial infarction and heart failure in the emergency department.
-
Guidants (Indianapolis, Indiana) Vascular Intervention division (Santa Clara, California) has acquired the right to use certain bioabsorbable polymer technologies developed by MediVas (San Diego, California), a firm that primarily focuses on developing technologies for diagnosis and treatment of cardiovascular diseases.
-
Novoste (Norcross, Georgia), a specialist in brachytherapy technology for the prevention of in-stent restenosis, reported last month that it would lay off 50 employees, mostly at its Norcross location, in ongoing moves to cut costs and restructure operations.
-
Cardiac Science (Irvine, California) and GE Medical Systems Information Technologies (GEMSIT; Milwaukee, Wisconsin) have signed multi-year strategic OEM, distribution and development agreements, under which GE will market Cardiac Science automated external defibrillators (AEDs) and fully-automatic in-hospital defibrillator-monitors (CRMs) under the GE name in Europe, Asia, the Middle East and other international markets.
-
A new filter device designed to capture the emboli and aortic plaque caused by cross-clamping of the aorta during a cardiopulmonary bypass procedure began commercial launch in the U.S. last month, and could potentially benefit hundreds of thousands of patients worldwide. Edwards Lifesciences (Irvine, California) said it has begun U.S. launch of the Embol-X intra-aortic embolic management system.
